Advertising Opportunities
Biosimilar medicines' developments are maintaining their momentum, and the 2018 Biosimilars Conference programme delves into strategic discussions regarding Market access and regulatory developments in the EU and globally, National policy developments and the impact of biosimilar medicines on the competitive landscape of biological products and the sustainability of the biosimilar medicines sector.
Target Audience
This conference is targetting professionals:
Advertising Prospectus
Please download our Advertising Prospectus to see all the opportunities available at this forum.
If you would like further information please email DIAexhibition@kit-group.org
Media Partner Information
Generics and Biosimilars Initiative (GaBI) was founded in 2008. GaBI aims to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care.
The objective of GaBI is to raise the scientific status of generic and biosimilar medicines, via well-documented and up-to-date information about generic and biosimilar medicines both in print (www.gabi-journal.net) and electronically (www.gabionline.net) in an open access format, provid-ing high quality, scientifically sound and reliable information to healthcare professionals including physicians, pharmacists and nurses, consum-ers, drug developers, third-party payers, legislators and assessors; who are in need of a reliable, critical and independent source of information on all aspects of generic and biosimilar medicines.
Subscribe to gain easy access of information on the latest scientific research and developments in generic and biosimilar medicines via GaBI Online to editorial@gabionline.net; or submit a manuscript to GaBI Journal to editorial@gabi-journal.net.
GaBI’s mission – Building trust in cost-effective treatments
